Supply Chain Intelligence

Ultragenyx Pharmaceutical Inc. Supply Chain

RARE supply chain intelligence for Ultragenyx Pharmaceutical Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

RARE ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
10Customers
2Debt Items
20Related Chains

Ultragenyx Pharmaceutical Inc. Suppliers

TickerNameConfidenceEvidence
REGENERON REGENERON 92% Under the collaboration agreement, Regeneron supplies the product and charges the Company a product purchase price from the low 20 % range up to 40 % on net sales, which is recognized as cost of sales
GENETX GENETX 90% In July 2022, pursuant to the terms of the Unitholder Option Agreement, as amended, we exercised the Option to acquire GeneTx and entered into a Unit Purchase Agreement, or the Purchase Agreement, pu…
RGNX REGENXBIO Inc. 72% Reciprocal relationship from RGNX graph: Reciprocal relationship from RARE graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from RARE graph: Reciprocal relationship from RGNX g…

Ultragenyx Pharmaceutical Inc. Customers

TickerNameConfidenceEvidence
RESEARCH-AGREEMENTS-KYOWA-KIRIN-CO-LTD RESEARCH-AGREEMENTS-KYOWA-KIRIN-CO-LTD 85% ts (continued) 9. License and Research Agreements Kyowa Kirin Co., Ltd. In August 2013, the Company entered into a collaboration and license agreement with Kyowa Kirin Co., Ltd., or KKC. Under the te…
MNPR Monopar Therapeutics Inc. 72% Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities …
RGNX REGENXBIO Inc. 72% Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that …
AENOVA-HAUPT-PHARMA-WOLFRATSHAUSEN-GMBH AENOVA-HAUPT-PHARMA-WOLFRATSHAUSEN-GMBH 62% ch was subsequently amended, with Baylor Research Institute, or BRI, under which we exclusively licensed certain intellectual property related to Dojolvi. The license includes patents, patent applica…
BAXTER-PHARMACEUTICAL-SOLUTIONS-LLC BAXTER-PHARMACEUTICAL-SOLUTIONS-LLC 62% ch was subsequently amended, with Baylor Research Institute, or BRI, under which we exclusively licensed certain intellectual property related to Dojolvi. The license includes patents, patent applica…
CLINICAL-PRODUCT-CANDIDATES-REGENXBIO-INC CLINICAL-PRODUCT-CANDIDATES-REGENXBIO-INC 62% ch was subsequently amended, with Baylor Research Institute, or BRI, under which we exclusively licensed certain intellectual property related to Dojolvi. The license includes patents, patent applica…
IOI-OLEO-GMBH IOI-OLEO-GMBH 62% ch was subsequently amended, with Baylor Research Institute, or BRI, under which we exclusively licensed certain intellectual property related to Dojolvi. The license includes patents, patent applica…
OSSIFI-MAB-LLC OSSIFI-MAB-LLC 62% d strategy and may encounter difficulties in allocating sufficient resources to sales and marketing of certain products. Further, as we launch additional products or as demand for our products change…
PRECLINICAL-PIPELINE-SOLID-BIOSCIENCES-INC PRECLINICAL-PIPELINE-SOLID-BIOSCIENCES-INC 62% ch was subsequently amended, with Baylor Research Institute, or BRI, under which we exclusively licensed certain intellectual property related to Dojolvi. The license includes patents, patent applica…
WUXI-APPTECH-CO WUXI-APPTECH-CO 62% eement may also be less favorable or more costly than the terms we have with our current supplier. A delay in the commercialization of our products or the development of our product candidates or hav…

Ultragenyx Pharmaceutical Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
RARE-DEBT-12054 Xbrl Convertible 90% xbrl convertible detail from xbrl 2014-12-31.
RARE-DEBT Debt stack $1.2B 90% Market cache reports total debt of $1.2B.

Ultragenyx Pharmaceutical Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Ultragenyx Pharmaceutical Inc..

Ultragenyx Pharmaceutical Inc. Ownership

HolderNameConfidenceEvidence
RARE-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 297 tracked holders.

Ultragenyx Pharmaceutical Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
MYGN Myriad Genetics, Inc. 100.00 2
SRPT Sarepta Therapeutics, Inc. 100.00 2
LXEO Lexeo Therapeutics, Inc. 100.00 2
INSM Insmed Incorporated 100.00 2
RGNX REGENXBIO Inc. 100.00 1 ['customer', 'supplier']
TRDA Entrada Therapeutics, Inc. 100.00 2
OTLK Outlook Therapeutics, Inc. 50.00 2
DNLI Denali Therapeutics Inc. 50.00 2
TNYA Tenaya Therapeutics, Inc. 50.00 2
TLX Telix Pharmaceuticals Limited 50.00 2
XOMA XOMA Royalty Corporation 50.00 2
NVSEF Novartis AG 50.00 2
BHC Bausch Health Companies Inc. 50.00 2
REGN Regeneron Pharmaceuticals, Inc. 50.00 2
ETON Eton Pharmaceuticals, Inc. 50.00 2
TSHA Taysha Gene Therapies, Inc. 50.00 2
FDMT 4D Molecular Therapeutics, Inc. 50.00 2
LNTH Lantheus Holdings, Inc. 50.00 2
ATNM Actinium Pharmaceuticals, Inc. 50.00 2
JNJ Johnson & Johnson 50.00 2
View RARE supply chain intel →

Explore the full interactive supply chain map for Ultragenyx Pharmaceutical Inc..

Open RARE supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map